<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Dec. 11, 2019 (HealthDay News) — Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, according to a study published online Dec. 11 in the New England Journal of Medicine<\/i> to coincide with the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 14 in Texas.<\/p>\n
Rashmi K. Murthy, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues randomly assigned patients with HER2-positive metastatic breast cancer, with or without brain metastases, previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, to receive either tucatinib or placebo in combination with trastuzumab and capecitabine.<\/p>\n
The researchers found that progression-free survival at one year was 33.1 and 12.3 percent in the tucatinib- and placebo-combination groups, respectively (hazard ratio for disease progression or death, 0.54), with median duration of progression-free survival of 7.8 and 5.6 months, respectively. At two years, overall survival was 44.9 and 26.6 percent in the tucatinib- and placebo-combination groups, respectively (hazard ratio for death, 0.66), with median overall survival of 21.9 and 17.4 months, respectively. Progression-free survival at one year was 24.9 and 0 percent in the tucatinib- and placebo-combination groups, respectively, among patients with brain metastases (hazard ratio, 0.48), with median progression-free survival of 7.6 and 5.4 months, respectively.<\/p>\n
“Tucatinib plus trastuzumab and capecitabine is an active combination in heavily pretreated patients with HER2-positive metastatic breast cancer, including those with previously untreated, treated and stable, or treated and progressing brain metastases,” the authors write.<\/p>\n
The study was funded by Seattle Genetics, the manufacturer of tucatinib.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n